Inhibition of p38 MAPK activity in B-NHL Raji cells by treatment with engineered CD20-specific T cells

Vega MI, Huerta-Yepez S, Jazirehi AR, Garban H and Bonavida B: Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene. 24:8114–8127. 2005.PubMed/NCBI

Vega MI, Huerta-Yepaz S, Garban H, Jazirehi A, Emmanouilides C and Bonavida B: Rituximab inhibits p38 MAPK activity in 2F7 B NHL and decreases IL-10 transcription: pivotal role of p38 MAPK in drug resistance. Oncogene. 23:3530–3540. 2004. View Article : Google Scholar : PubMed/NCBI

Till BG and Press OW: Treatment of lymphoma with adoptively transferred T cells. Expert Opin Biol Ther. 9:1407–1425. 2009. View Article : Google Scholar : PubMed/NCBI

Jensen MC, Cooper LJ, Wu AM, Forman SJ and Raubitschek A: Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy. Cytotherapy. 5:131–138. 2003. View Article : Google Scholar : PubMed/NCBI

Eshhar Z, Waks T, Gross G and Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T cell receptors. Proc Natl Acad Sci USA. 90:720–724. 1993. View Article : Google Scholar

Hombach A, Wieczarkowiecz A, Marquardt T, et al: Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule. J Immunol. 167:6123–6131. 2001. View Article : Google Scholar

Yu K, Hu Y, Tan Y, et al: Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene. Leuk Lymphoma. 49:1368–1373. 2008. View Article : Google Scholar : PubMed/NCBI

Zheng Y, Yu K, Du J, et al: Potential therapeutic strategy for non-Hodgkin lymphoma by anti-CD20scFvFc/CD28/CD3zeta gene transfected T cells. J Exp Clin Cancer Res. 29:1212010. View Article : Google Scholar : PubMed/NCBI

Jiang L, Chen Y, Chan CY, et al: Down-regulation of stathmin is required for TGF-beta inducible early gene 1 induced growth inhibition of pancreatic cancer cells. Cancer Lett. 274:101–108. 2009. View Article : Google Scholar : PubMed/NCBI

Wang H, Wei H, Zhang R, et al: Genetically targeted T cells eradicate established breast cancer in syngeneic mice. Clin Cancer Res. 15:943–950. 2009. View Article : Google Scholar : PubMed/NCBI

Teng MW, Kershaw MH, Moeller M, Smyth MJ and Darcy PK: Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes. Hum Gene Ther. 15:699–708. 2004. View Article : Google Scholar : PubMed/NCBI

Haynes NM, Trapani JA, Teng MW, et al: Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors. Blood. 100:3155–3163. 2002. View Article : Google Scholar

Rossig C and Brenner MK: Genetic modification of T lymphocytes for adoptive immunotherapy. Mol Ther. 10:5–18. 2004. View Article : Google Scholar : PubMed/NCBI

Finney HM, Akbar AN and Lawson AD: Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain. J Immunol. 172:104–113. 2004. View Article : Google Scholar : PubMed/NCBI

El-Far M, Fouda M, Yahya R and el-Baz H: Serum IL-10 and IL-6 levels at diagnosis as independent predictors of outcome in non-Hodgkin’s lymphoma. J Physiol Biochem. 60:253–258. 2004.PubMed/NCBI

Voorzanger N, Touitou R, Garcia E, et al: Interleukin (IL)-10 and IL-6 are produced in vivo by non-Hodgkin’s lymphoma cells and act as cooperative growth factors. Cancer Res. 56:5499–5505. 1996.PubMed/NCBI

Benjamin D, Park CD and Sharma V: Human B cell interleukin 10. Leuk Lymphoma. 12:205–210. 1994. View Article : Google Scholar

Alas S, Emmanouilides C and Bonavida B: Inhibition of interleukin 10 by rituximab results in down-regulation of bcl-2 and sensitization of B-cell non-Hodgkin’s lymphoma to apoptosis. Clin Cancer Res. 7:709–723. 2001.PubMed/NCBI

Vockerodt M, Haier B, Buttgereit P, Tesch H and Kube D: The Epstein-Barr virus latent membrane protein 1 induces interleukin-10 in Burkitt’s lymphoma cells but not in Hodgkin’s cells involving the p38/SAPK2 pathway. Virology. 280:183–198. 2001.

Platanias LC: Map kinase signaling pathways and hematologic malignancies. Blood. 101:4667–4679. 2003. View Article : Google Scholar : PubMed/NCBI

Pedersen IM, Buhl AM, Klausen P, Geisler CH and Jurlander J: The chimeric anti-CD20 antibody rituximab induces apoptosis in B-cell chronic lymphocytic leukemia cells through a p38 mitogen activated protein-kinase-dependent mechanism. Blood. 99:1314–1319. 2002. View Article : Google Scholar

Jazirehi AR, Gan XH, De Vos S, Emmanouilides C and Bonavida B: Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin’s lymphoma B cell lines to paclitaxel-induced apoptosis. Mol Cancer Ther. 2:1183–1193. 2003.PubMed/NCBI

Alas S and Bonavida B: Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin’s lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res. 61:5137–5144. 2001.PubMed/NCBI

Ma W, Lim W, Gee K, et al: The p38 mitogen-activated kinase pathway regulates the human interleukin-10 promoter via the activation of Sp1 transcription factor in lipopolysaccharide-stimulated human macrophages. J Biol Chem. 276:13664–13674. 2001.